Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in ...
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a Jerusalem, Israel-based emerging biopharmaceutical company built around two connected activities: (1) research and development of inflammation and immunology therapies, and (2) provision of boutique contract development and manufacturing services (CDMO) for biologics. The company’s therapeutic platform centers on NanoAb (nanosized antibody) technology, including ...Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a Jerusalem, Israel-based emerging biopharmaceutical company built around two connected activities: (1) research and development of inflammation and immunology therapies, and (2) provision of boutique contract development and manufacturing services (CDMO) for biologics. The company’s therapeutic platform centers on NanoAb (nanosized antibody) technology, including VHH antibody fragments, engineered for unique physicochemical properties and designed to support targeting and development across multiple indications.
From a business perspective, Scinai’s model combines product-oriented drug development with services-based revenue potential via its CDMO offering. This structure can diversify opportunity: while clinical and regulatory progress drives long-term value for proprietary therapeutics, CDMO engagements can support funding continuity and provide applied development experience. The company has described a significant licensing/collaboration relationship with the Max Planck Society and University Medical Center Göttingen, including work around a NanoAb approach originally highlighted for COVID-19 and then extended to other disease indications.
Product and service scope is aligned with “concept to GMP manufacturing,” indicating end-to-end support typical of biologics development programs. In practice, this can include analytical development, formulation/process development, and manufacturing under GMP standards—capabilities that are often valuable to sponsors that need reliable execution without building full internal infrastructure. Scinai’s CDMO platform has also been presented as an expansion of its services business (e.g., via a dedicated business unit such as Scinai Bioservices referenced in public materials).
Cost and BOM considerations for a biotech CDMO typically involve specialized inputs (cell culture media, buffers, chromatography resins, single-use consumables, reference standards, and QA/QC consumables), plus substantial overhead for regulated documentation, validation/qualification, and quality systems. While exact bill-of-materials figures are not provided here, the company’s positioning as a boutique CDMO implies a focus on efficient, sponsor-facing delivery of biologics work packages rather than commodity-scale production.
Financially, the provided TTM indicators show negative profitability metrics (e.g., negative operating and net margins) and negative free cash flow measures—common for early-stage biopharma companies investing in R&D, manufacturing capability, and platform growth. Liquidity/solvency ratios in the dataset suggest the firm is not distressed in the conventional sense (e.g., current ratio above 1), but cash generation remains constrained, which is typical for companies balancing R&D with scaling services operations.
Key people include Amir Reichman (CEO), appointed as CEO in 2021, alongside senior leadership such as Elad Mark (COO) and Uri Ben-or (CFO) as referenced in publicly available leadership listings. With a relatively small workforce (approximately mid-40s to low-50s), Scinai operates as a lean organization where cross-functional roles and rapid execution are critical to moving programs from research through development and manufacturing.
Overall, Scinai’s “wishes” and strategic emphasis implied by its public materials are to (a) advance NanoAb-based immunology/inflammation therapeutics toward commercialization readiness and (b) grow its CDMO platform as a durable services engine that complements proprietary development—strengthening both execution capability and the company’s path to sustainable financial performance.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$1.3M
+99.2%
-4.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-8.3M
-273.2%
-157.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-202.3%
-129.5%
-19.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-575.3%
+56.2%
+7.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-633.6%
-186.9%
-159.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-6.1M
+4.6%
-79.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-461.9%
+52.1%
-86.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
28.0%
+33.8%
+2.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.30x
-2.1%
+16.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Andrew Eriksen: All right. I think we're live now, so let's jump in. Thank you, everyone, for joining today, Scinai Immunotherapeutics corporate overview and 2026 midyear business update. My name is Andrew Eriksen. I'm a Managing Director here at Allele Capital, who works directly with the Scinai team, and we're helping kind of put on this event today. So we're going to run through a bit of the first half results that you might have noticed Scinai published just yesterday, review some of those financials, some of those business updates, and then Amir is going to give us a bit of an outlook for the rest of 2026 and why the team is ultimately really excited about what's to come. So without further ado, we'll get into it, and then we'll save the questions at the end. If you're watching on LinkedIn or YouTube, there's chat boxes for both of those platforms, so submit your questions, and we'll get to those at the end of the conversation. So without further ado, let's jump into the call here, Amir. Maybe what you can do is, I'm sure a lot of people on the call are familiar with who you are, but maybe just a quick background on yourself and your role at Scinai and then we can get into some of the first half details.
Amir Reichman: Thank you very much, Andrew, and welcome, everybody, to our webinar today. I'm Amir Reichman. I have a biotechnology engineering master's degree and an MBA from the Wharton School of Penn University. My background goes back more than 20 years in pharmaceutical industry between the United States, Europe and Israel. Now I'm leading Scinai as the CEO of Scinai Immunotherapeutics, the parent company and also of the subsidiary, Scinai Biopharma Services, our CDMO daughter company.
Andrew Eriksen: With that, let's kind of jump in. So as we discussed, the first half results got published yesterday, I think there was a lot of positives coming out of that. But before we get into the individual numbers, can you put the first half of 2026 into perspective for investors, Amir? What changed at Scinai? Where does the company stand today versus the beginning of the year?
Amir Reichman: Yes. The day before yesterday, time flies. So I think the most important way to look at the first half of 2026 is that Scinai today is materially different company than the one that entered the year. At the beginning of 2026, we had our innovative immunology R&D pipeline and an emerging CDMO business in Jerusalem. During the first half, we significantly expanded the commercial side of the company through the acquisition of former Recipharm operations in Yavne, Israel. That transaction added much more than equipment and infrastructure, it added an experienced operating team, established quality systems, technical know-how, customer relationships, and additional manufacturing capabilities. So today, Scinai has two complementary value-creating platforms, our immunology R&D activities and the broader two site CDMO business operating in Jerusalem and Yavne, …
